Study guide
12.4 Expanded Scope: Adapting, Renewing, Initiating, and Medication Reconciliation
PEBC Pharmacist Evaluating Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & The Canadian Pharmacy Practice Landscape
1.1 PEBC EE Blueprint, Format, Scoring, and IPG Certification Pathway 1.2 The Canadian Healthcare System, Canada Health Act, and Drug Regulation 1.3 Canadian Pharmacy Regulatory Framework, NAPRA Standards, and Professional Legislation
2 Chapter 2: Pharmaceutics & Drug Delivery Systems
2.1 Physicochemical Principles, Solubility, Ionization, and Stability 2.2 Solid Dosage Forms, Formulation Science, and Modified-Release Technologies 2.3 Liquid and Semisolid Dosage Forms, Dispersions, and Topical Delivery 2.4 Sterile Product Principles, Parenteral Delivery, and Biopharmaceuticals 2.5 Pharmaceutical Quality: GMP, Stability Testing, and Bioequivalence
3 Chapter 3: Biopharmaceutics & Clinical Pharmacokinetics
3.1 Drug Absorption, Distribution, Metabolism, and Elimination (ADME) 3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS) 3.3 Pharmacokinetic Modeling, Parameters, and Dosing Calculations 3.4 Therapeutic Drug Monitoring (TDM) and Clinical Application
4 Chapter 4: Pharmacology, Toxicology & Pharmacogenetics
4.1 Autonomic and Central Nervous System Pharmacology 4.2 Cardiovascular, Renal, and Endocrine Pharmacology 4.3 Clinical Toxicology, Overdose Management, and Antidotes 4.4 Biologics, Biosimilars, and Pharmacogenetics
5 Chapter 5: Pathophysiology & Clinical Assessment
5.1 Clinical Laboratory Diagnostics, Biomarkers, and Vital Signs 5.2 Cardiovascular and Respiratory Pathophysiology 5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology 5.4 Neurologic, Psychiatric, and Musculoskeletal Pathophysiology 5.5 Physical Assessment and Point-of-Care Testing
6 Chapter 6: Pharmacotherapy & Minor Ailments
6.1 Cardiovascular Pharmacotherapy & Evidence-Based Guidelines 6.2 Endocrine and Metabolic Pharmacotherapy 6.3 Infectious Diseases and Antimicrobial Stewardship 6.4 Neurologic, Psychiatric, and Pain Management Therapeutics 6.5 Minor Ailment Prescribing and Nonprescription Therapy 6.6 Respiratory Pharmacotherapy: Asthma, COPD, and Inhaled Therapy 6.7 Gastrointestinal and Hepatic Pharmacotherapy 6.8 Renal, Fluid, and Electrolyte Therapeutics 6.9 Musculoskeletal and Rheumatologic Pharmacotherapy 6.10 Dermatologic, Ophthalmic, and Ear-Nose-Throat Pharmacotherapy 6.11 Hematologic, Immunologic, and Oncology Supportive Care 6.12 Women's Health, Men's Health, and Urologic Therapeutics 6.13 Nutrition, Natural Health Products, and Complementary Medicine
7 Chapter 7: Special Populations & Applied Therapeutics
7.1 Geriatric Pharmacotherapy and Deprescribing 7.2 Pediatric and Neonatal Pharmacotherapy 7.3 Perinatal Pharmacotherapy: Pregnancy and Lactation 7.4 Dosage Adjustments in Renal and Hepatic Impairment
8 Chapter 8: Prescription Processing, Calculations & Compounding
8.1 Prescription Processing, Verification, and Drug Therapy Problem Management 8.2 Pharmaceutical Calculations and Clinical Math 8.3 Non-Sterile Compounding and NAPRA Standards 8.4 Sterile and Hazardous Compounding under NAPRA Standards 8.5 Advanced Calculations: Infusion Rates, Parenteral Nutrition, and Renal Estimation
9 Chapter 9: Health Equity, Indigenous Health & Pharmacy Bioethics
9.1 Social Determinants of Health and Health Equity 9.2 Indigenous Health, Cultural Safety, and Humility 9.3 Pharmacy Bioethics, Informed Consent, and Professional Boundaries 9.4 Health Promotion, Disease Prevention, and Public Health
10 Chapter 10: Evidence Appraisal, Safety & Practice Management
10.1 Biostatistics and Critical Appraisal of Clinical Literature 10.2 Pharmacoeconomics and Pharmacoepidemiology 10.3 Medication Safety, Incident Analysis, and Quality Improvement 10.4 Pharmacy Operations, Cold-Chain Management, and Emergency Preparedness 10.5 Drug Information and Evidence-Based Decision Making 10.6 Pharmacovigilance and Adverse Drug Reaction Reporting in Canada
11 Chapter 11: Patient Care Process, Communication & Collaborative Practice
11.1 The Patient Care Process: Assessment, Care Plans, and Follow-Up 11.2 Patient and Caregiver Communication, Education, and Health Literacy 11.3 Motivational Interviewing and Shared Decision-Making 11.4 Intra- and Interprofessional Collaborative Care
12 Chapter 12: Medication Administration, Devices & Expanded Scope
12.1 Injection and Vaccine Administration Technique 12.2 Immunization Schedules, Vaccine Selection, and Travel Health 12.3 Home Medical Devices and Device Technique Coaching 12.4 Expanded Scope: Adapting, Renewing, Initiating, and Medication Reconciliation
13 Chapter 13: Pharmacy Management, Finance & Practice Leadership
13.1 Human Resources, Leadership, and Change Management 13.2 Financial Management, Drug Plans, and Marketing 13.3 Quality Improvement, Risk Management, and Workplace Safety
12.4 Expanded Scope: Adapting, Renewing, Initiating, and Medication Reconciliation
Key Takeaways Explain This Topic AI
Adapting a prescription means changing the dose, formulation, or regimen of an existing prescription; renewing means continuing therapy for continuity of care; initiating means starting new therapy under provincial authority.
Every expanded-scope activity requires an assessment, documentation, and notification of the original prescriber, and the pharmacist assumes accountability for the decision.
Therapeutic substitution is a change to a different drug and generally requires specific authority, distinct from generic interchange under provincial drug plan rules.
Medication reconciliation compares a best possible medication history against active orders and resolves each discrepancy as intentional, undocumented intentional, or unintentional.
Unintentional discrepancies at transitions of care are the most common source of preventable harm in the medication use process.
Last updated: August 2026
12.4 Expanded Scope: Adapting, Renewing, Initiating, and Medication Reconciliation
Exam Focus: The syllabus names "skills required for expanded scope of practice including renewing, modifying, and initiating pharmacotherapy, as well as deprescribing" and "medication reconciliation" and "use of pharmacy information technology" as explicit bullets. Items test whether the specific act is within scope and whether the required documentation and notification occurred.
Understanding the Vocabulary
Scope varies substantially by province, so the examination tests the concept and the professional obligations , not one province's list. Confirm your own jurisdiction's authority in practice.
Activity Definition Example
Adapt or modify Change the dose, formulation, regimen, or route of an existing prescription Changing metformin 1,000 mg once daily to 500 mg twice daily to reduce gastrointestinal upset
Renew or extend Continue an existing therapy for continuity of care when the prescriber is unavailable Providing a further 3 months of an antihypertensive while an appointment is arranged
Therapeutic substitution Change to a different drug, usually within the same class Changing one proton pump inhibitor to another when supply fails
Initiate Start new therapy where provincial authority permits Prescribing for a listed minor ailment, or smoking cessation therapy
Deprescribe Systematically taper or stop a drug that is no longer of net benefit Tapering long-term benzodiazepine therapy in an older adult
Generic interchange under provincial drug plan rules — substituting a bioequivalent product with the same active ingredient — is a separate concept from therapeutic substitution, and it does not require prescriber authorisation in the same way. Narrow-therapeutic-index products such as levothyroxine, warfarin, and antiepileptics warrant caution and consistency in brand even where interchange is permitted.
The Obligations Attached to Every Expanded-Scope Act
Whatever the province, the same professional structure applies:
Assess. Confirm the diagnosis and indication, review the full profile, evaluate effectiveness and safety, and establish that the patient's condition is stable and appropriate for the action.
Confirm the act is within scope. Some provinces exclude controlled substances, restrict initiation to specified conditions, or limit the duration of a renewal.
Obtain informed consent. Explain what is being changed and why.
Act, and accept accountability. A pharmacist who adapts or initiates therapy is responsible for that decision on the same footing as any prescriber.
Document. Record the assessment, the rationale, the action, the monitoring plan, and the follow-up date.
Notify the original prescriber , in the manner and within the timeframe the province requires.
Follow up. Confirm the intended outcome was achieved and no new problem arose.
Situations that generally fall outside adaptation: changing therapy where the diagnosis is uncertain, a patient who is unstable or deteriorating, therapy that requires monitoring the pharmacist cannot access, and any change the patient does not consent to. In those cases the correct action is to contact the prescriber.
Minor ailment prescribing now exists in most provinces, with each publishing its own list of eligible conditions, its own assessment forms, and its own exclusion criteria. Common inclusions are uncomplicated urinary tract infection, allergic rhinitis, cold sores, dermatitis, oral thrush, and hemorrhoids. Every provincial framework requires red-flag screening and referral criteria; the pharmacist's most important judgement is often the decision not to prescribe.
Deprescribing
Deprescribing is the planned, supervised reduction or cessation of a drug whose harms now outweigh its benefits. It is an active clinical intervention, not the absence of one.
Priority targets in Canadian practice include long-term proton pump inhibitors without an ongoing indication, benzodiazepines and Z-drugs for insomnia in older adults, antipsychotics used for the behavioural and psychological symptoms of dementia, sulfonylureas causing hypoglycemia, and anticholinergics contributing to cognitive burden.
The method: identify the drug and confirm the absence of an ongoing indication; discuss the benefits and risks with the patient and family; taper rather than stop abruptly where withdrawal or rebound is expected — benzodiazepines, opioids, corticosteroids, beta-blockers, proton pump inhibitors, antidepressants; set explicit monitoring for symptom return; and document a plan for what happens if symptoms recur. Tell the patient in advance that a symptom might return, which prevents an expected withdrawal effect being interpreted as proof that the drug was essential.
Medication Reconciliation
Medication reconciliation is a formal process: create a best possible medication history, compare it against the medications ordered at the transition point, identify and classify every discrepancy, resolve it with the prescriber, and communicate the reconciled list.
Discrepancy type Meaning Action
Intentional, documented The change was deliberate and recorded No action beyond confirming the patient understands
Intentional, undocumented The change was deliberate but the reason is not recorded Clarify and document, so the next clinician does not reverse it
Unintentional Omission, duplication, or wrong dose, route, or frequency Resolve with the prescriber; this is where preventable harm concentrates
Reconciliation is required at admission, internal transfer, and discharge , and it is equally valuable in the community after a hospital stay or a specialist visit. The most common unintentional discrepancy is the omission of a chronic medication that was held during the admission and never restarted.
Pharmacy Information Technology
Technology supports these activities but does not replace judgement.
Provincial drug information systems give a view of dispensing across pharmacies, which strengthens a best possible medication history and supports controlled-substance monitoring.
Clinical decision support flags interactions and allergies. Alert fatigue is the predictable hazard: when most alerts are low value, high-value alerts are dismissed with the rest, so systems must be tuned rather than simply enabled.
Electronic prescribing removes handwriting error and transcription risk, but introduces selection error from adjacent entries in a drop-down list.
Automated dispensing and pouch packaging improve accuracy and adherence but require the same final verification as any other product.
Privacy obligations apply to every one of these systems. Access personal health information only for a professional purpose, on a need-to-know basis, and under the applicable federal or provincial privacy legislation.